Our study discovered that anti-PD-L1 monotherapy was more closely related to thyroid dysfunction and can induce a small number of other endocrine ADRs, such as type 1 diabetes mellitus, hypophysitis and adrenal insufficiency. Here, CD274 is linked to diabetes mellitus.